Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3U19AI100625-08S1

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $563,507
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    University of North Carolina at Chapel Hill
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Abstract: Emerging viruses, such as SARS-CoV, influenza A virus (IAV), and West Nile virus (WNV) causehigh levels of morbidity and mortality in Human populations. Host immune responses can play either protectiveor a pathologic role during viral infections. Therefore, understanding of the regulatory networks and signalingpathways that determine the magnitude and quality of an individual's antiviral immune response has importantimplications for human health, since these genes/pathways could be therapeutically targeted to treat virus-induced disease, or may represent targets for enhancing the safety and efficacy of vaccines against a widerange of viral pathogens.Polymorphic host genes and regulatory networks have a major impact on immune response variation in humanpopulations. However, confounding environmental factors and/or ethical concerns limit the types of studiesthat can be conducted in humans. Therefore, genetically tractable model systems that capture the range ofgenetic and phenotypic diversity seen in humans, such as the Collaborative Cross (CC) are needed tomechanistically dissect the genetics of immune variation. Our research team has quantified variation inbaseline, as well as SARS-CoV, IAV, and WNV-induced immune responses in a panel of 110 CC RIX lines(reproducible F1 crosses between CC recombinant inbred (RI) lines that model heterozygous humanpopulations). To our knowledge, this represents to most comprehensive analysis of immune response variationever conducted in a genetic reference population, and in ongoing QTL mapping studies, we have identified100+ quantitative trait loci (QTL) associated with variation in virus-induced innate and adaptive immunity,inflammation and disease. Our program, which includes expertise in viral pathogenesis, innate and adaptiveimmunity, and quantitative genetics will use this unprecedented data base to: 1) identify and characterizepolymorphic host genes that drive variation in virus-induced disease, 2) test how interactions between differentpolymorphic genes/loci shape the host immune response, 3) test how these genes impact responses to otherviral pathogens, or function during allergy/auto-immunity, and 4) test the impact of these genes in the contextof human infections to identify targets for diagnosis, prevention and therapeutic interventions in humans.These studies will significantly enhance our understanding of how host genetic variation shapes virus-inducedimmunity and/or disease.